Company intelligence / Profile preview

Dynacord

Illkirch-Graffenstaden, Grand Est, France

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Dynacure is a clinical-stage biotechnology company focused on developing novel therapies for rare and orphan neuromuscular diseases. The company's lead program, DYN101, is an antisense oligonucleotide designed to reduce the expression of Dynamin 2 (DNM2) for the treatment of centronuclear myopathies (CNM). By targeting the underlying genetic cause of these debilitating muscle disorders, Dynacure aims to provide disease-modifying treatments where none currently exist. The company leverages a strategic partnership with Ionis Pharmaceuticals to utilize advanced antisense technology in its development pipeline.

Therapeutic areas: Rare Diseases
Modalities: Antisense oligonucleotideRNA therapy
Industry: Biotech

Partnerships

Ionis Pharmaceuticals

Beyond the preview

Go deeper on Dynacord.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dynacord.

Explore the full profile